Abhay Joshi
2017
In 2017, Abhay Joshi earned a total compensation of $2M as Chief Operating Officer at Revance Therapeutics, a 44% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $344,728 |
|---|---|
| Option Awards | $971,289 |
| Salary | $453,200 |
| Stock Awards | $258,070 |
| Total | $2,027,287 |
Joshi received $971.3K in option awards, accounting for 48% of the total pay in 2017.
Joshi also received $344.7K in non-equity incentive plan, $453.2K in salary and $258.1K in stock awards.
Rankings
In 2017, Abhay Joshi's compensation ranked 5,434th out of 14,666 executives tracked by ExecPay. In other words, Joshi earned more than 62.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,434 out of 14,666 | 63rd |
Division Manufacturing | 1,950 out of 5,768 | 66th |
Major group Chemicals And Allied Products | 584 out of 2,074 | 72nd |
Industry group Drugs | 449 out of 1,730 | 74th |
Industry Pharmaceutical Preparations | 354 out of 1,329 | 73rd |
Source: SEC filing on March 20, 2018.
Joshi's colleagues
We found three more compensation records of executives who worked with Abhay Joshi at Revance Therapeutics in 2017.
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019